Alexander Hartenstein

Dr. Alexander Hartenstein

Bayer

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2023 in Radiology
Verified
Journal Article
Closed access
CHCharlie Alexander Hamm
Charlie Alexander Hamm
Georg Lukas BaumgärtnerGeorg Lukas Baumgärtner
Georg Lukas Baumgärtner
FBFelix Biessmann
Felix Biessmann
NBNick Lasse Beetz
Nick Lasse Beetz
AHAlexander Hartenstein
Alexander Hartenstein
TPTobias Penzkofer
Tobias Penzkofer
Background Clinically significant prostate cancer (PCa) diagnosis at MRI requires accurate and efficient radiologic interpretation. Although artificial intelligence may assist in this task, lack of transparency has limited clinical translation. Purpose To develop an explainable artificial intelligence (XAI) model for clinically significant PCa diagnosis at biparametric MRI using Prostate Imaging Reporting and Data System (PI-RADS) features for classification justification. Materials and Methods This retrospective study included consecutive patients with histopathologic analysis-proven prostatic lesions who underwent biparametric MRI and biopsy between January 2012 and December 2017. After image annotation by two radiologists, a deep learning model was trained to detect the index lesion; classify PCa, clinically significant PCa (Gleason score ≥ 7), and benign lesions (eg, prostatitis); and justify classifications using PI-RADS features. Lesion- and patient-based performance were assessed using fivefold cross validation and areas under the receiver operating characteristic curve. Clinical feasibility was tested in a multireader study and by using the external PROSTATEx data set. Statistical evaluation of the multireader study included Mann-Whitney U and exact Fisher-Yates test. Results Overall, 1224 men (median age, 67 years; IQR, 62-73 years) had 3260 prostatic lesions (372 lesions with Gleason score of 6; 743 lesions with Gleason score of ≥ 7; 2145 benign lesions). XAI reliably detected clinically significant PCa in internal (area under the receiver operating characteristic curve, 0.89) and external test sets (area under the receiver operating characteristic curve, 0.87) with a sensitivity of 93% (95% CI: 87, 98) and an average of one false-positive finding per patient. Accuracy of the visual and textual explanations of XAI classifications was 80% (1080 of 1352), confirmed by experts. XAI-assisted readings improved the confidence (4.1 vs 3.4 on a five-point Likert scale; P = .007) of nonexperts in assessing PI-RADS 3 lesions, reducing reading time by 58 seconds (P = .009). Conclusion The explainable AI model reliably detected and classified clinically significant prostate cancer and improved the confidence and reading time of nonexperts while providing visual and textual explanations using well-established imaging features. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Chapiro in this issue.

26 March 2020 in European Radiology
Verified
Journal Article
Open access
PDF file
MRMadhuri M. Rudolph
Madhuri M. Rudolph
ABAlexander Baur
Alexander Baur
MHMatthias Haas
Matthias Haas
HCHannes Cash
Hannes Cash
KMKurt Miller
Kurt Miller
TPTobias Penzkofer
Tobias Penzkofer
Objectives: To assess the discriminatory power of lexicon terms used in PI-RADS version 2 to describe MRI features of prostate lesions. Methods: Four hundred fifty-four patients were included in this retrospective, institutional review board–approved study. Patients received multiparametric (mp) MRI and subsequent prostate biopsy including MRI/transrectal ultrasound fusion biopsy and 10-core systematic biopsy. PI-RADS lexicon terms describing lesion characteristics on mpMRI were assigned to lesions by experienced readers. Positive and negative predictive values (PPV, NPV) of each lexicon term were assessed using biopsy results as a reference standard. Results: From a total of 501 lesions, clinically significant prostate cancer (csPCa) was present in 175 lesions (34.9%). Terms related to findings of restricted diffusion showed PPVs of up to 52.0%/43.9% and NPV of up to 91.8%/89.7% (peripheral zone or PZ/transition zone or TZ). T2-weighted imaging (T2W)–related terms showed a wide range of predictive values. For PZ lesions, high PPVs were found for “markedly hypointense,” “lenticular,” “lobulated,” and “spiculated” (PPVs between 67.2 and 56.7%). For TZ lesions, high PPVs were found for “water-drop-shaped” and “erased charcoal sign” (78.6% and 61.0%). The terms “encapsulated,” “organized chaos,” and “linear” showed to be good predictors for benignity with distinctively low PPVs between 5.4 and 6.9%. Most T2WI-related terms showed improved predictive values for TZ lesions when combined with DWI-related findings. Conclusions: Lexicon terms with high discriminatory power were identified (e.g., “markedly hypointense,” “water-drop-shaped,” “organized chaos”). DWI-related terms can be useful for excluding TZ cancer. Combining T2WI- with DWI findings in TZ lesions markedly improved predictive values. Key Points: • Lexicon terms describing morphological and functional features of prostate lesions on MRI show a wide range of predictive values for prostate cancer. • Some T2-related terms have favorable PPVs, e.g., “water-drop-shaped” and “organized chaos” while others show less distinctive predictive values. DWI-related terms have noticeable negative predictive values in TZ lesions making DWI feature a useful tool for exclusion of TZ cancer. • Combining DWI- and T2-related lexicon terms for assessment of TZ lesions markedly improves PPVs. Most T2-related lexicon terms showed a significant decrease in PPV when combined with negative findings for “DW hyperintensity.”


16 January 2023 in International Journal of Population Data Science
Verified
Journal Article
Open access
PDF file
AHAlexander Hartenstein
Alexander Hartenstein
KAKhaled Abdelgawwad
Khaled Abdelgawwad
FKFrank Kleinjung
Frank Kleinjung
SPStephen Privitera
Stephen Privitera
TVThomas Viethen
Thomas Viethen
TVTatsiana Vaitsiakhovich
Tatsiana Vaitsiakhovich
IntroductionIn randomised controlled trials (RCTs), bleeding outcomes are often assessed using definitions provided by the International Society on Thrombosis and Haemostasis (ISTH). Information relating to bleeding events in real-world evidence (RWE) sources are not identified using these definitions. To assist with accurate comparisons between clinical trials and real-world studies, algorithms are required for the identification of ISTH-defined bleeding events in RWE sources. ObjectivesTo present a novel algorithm to identify ISTH-defined major and clinically-relevant non-major (CRNM) bleeding events in a US Electronic Health Record (EHR) database. MethodsThe ISTH definition for major bleeding was divided into three subclauses: fatal bleeds, critical organ bleeds and symptomatic bleeds associated with haemoglobin reductions. Data elements from EHRs required to identify patients fulfilling these subclauses (algorithm components) were defined according to International Classification of Diseases, 9th and 10th Revisions, Clinical Modification disease codes that describe key bleeding events. Other data providing context to bleeding severity included in the algorithm were: `interaction type' (diagnosis in the inpatient or outpatient setting), `position' (primary/discharge or secondary diagnosis), haemoglobin values from laboratory tests, blood transfusion codes and mortality data. ResultsIn the final algorithm, the components were combined to align with the subclauses of ISTH definitions for major and CRNM bleeds. A matrix was proposed to guide identification of ISTH bleeding events in the EHR database. The matrix categorises bleeding events by combining data from algorithm components, including: diagnosis codes, 'interaction type', 'position', decreases in haemoglobin concentrations (≥2 g/dL over 48 hours) and mortality. ConclusionsThe novel algorithm proposed here identifies ISTH major and CRNM bleeding events that are commonly investigated in RCTs in a real-world EHR data source. This algorithm could facilitate comparison between the frequency of bleeding outcomes recorded in clinical trials and RWE. Validation of algorithm performance is in progress.

16 May 2025 in Cardiology and Therapy
Verified
Journal Article
Open access
PDF file
TVTatsiana Vaitsiakhovich
Tatsiana Vaitsiakhovich
AHAlexander Hartenstein
Alexander Hartenstein
SPStephen Privitera
Stephen Privitera
MPManesh R. Patel
Manesh R. Patel
JPJonathan P. Piccini
Jonathan P. Piccini
FKFrank Kleinjung
Frank Kleinjung
Introduction The aim of this study was to assess the applicability of an external control arm (ECA) approach in the clinical development of the oral factor XIa inhibitor asundexian for stroke prevention in patients with atrial fibrillation (AF), using prospectively collected data from the phase 2 PACIFIC-AF trial (NCT04218266) and real-world individual-level data from patients with AF treated with apixaban in the Optum® de-identified Electronic Health Record data set (Optum® EHR) 2013–2019. Methods To build ECAs, real-world patients meeting trial eligibility criteria were matched to patients enrolled in PACIFIC-AF. The primary outcome was the composite of International Society on Thrombosis and Haemostasis–defined major bleeding or clinically relevant non-major bleeding. Event rates were compared between PACIFIC-AF and ECAs at 85 days of trial duration and projected up to 2 years. Results Overall, 160,153 real-world patients met PACIFIC-AF eligibility criteria and were matched to patients from the PACIFIC-AF apixaban arm on 101 variables, with matching ratios of 1:10, 1:5, and 1:1. At day 85, the number of events for the primary outcome was 92 (3.68%) in the 1:10 ECA (2500 patients) and 6 (2.40%) in the PACIFIC-AF apixaban arm (250 patients), with incidence rates of 16.67 (90% confidence interval [CI] 13.92–19.63) and 11.10 (90% CI 4.83–19.45) per 100 person-years, respectively. Conclusions ECAs matching the PACIFIC-AF apixaban arm could be built from EHRs with concordant event rates for key trial endpoints. The ECA approach enabled the determination of event rates for treatment duration up to 2 years, thereby informing the asundexian pivotal phase 3 trial in AF.

1 January 2025 in North Carolina Medical Journal
Verified
Journal Article
Open access
MAMonisa Aijaz
Monisa Aijaz
AHAlexander Hartenstein
Alexander Hartenstein
AHAsia Hardison
Asia Hardison
JKJames Kimani
James Kimani
ASAlison M. Stuebe
Alison M. Stuebe
APArrianna Marie Marie Planey
Arrianna Marie Marie Planey
This policy brief discusses North Carolina’s Care Management for High Risk Pregnancy Program (CMHRP), the state’s primary strategy for supporting Medicaid enrolled pregnant individuals at elevated risk for adverse maternal and birth outcomes. Research and survey results show that CMHRP improves health outcomes, is acceptable to Medicaid clients and staff, and aligns with local health department (LDH) missions, while also highlighting concerns about sustainability and resource constraints.